Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs
|
|
- Annabel Richards
- 5 years ago
- Views:
Transcription
1 Endocrine-Related Cancer (2008) Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs D Campana 1, F Nori 1, R Pezzilli 1, L Piscitelli 1, D Santini 2, E Brocchi 1, R Corinaldesi 1 and P Tomassetti 1 1 Dipartimento di Medicina Interna e Gastroenterologia and 2 Dipartimento Clinico di Scienze Radiologiche ed Istopatologiche, Università di Bologna, Bologna, Italy (Correspondence should be addressed to P Tomassetti, Department of Internal Medicine and Gastroenterology, University of Bologna, Policlinico S Orsola-Malpighi, Via Massarenti 9, Bologna, Italy; paola.tomassetti@unibo.it) Abstract Gastric endocrine tumors associated with autoimmune chronic atrophic gastritis (gastric carcinoid type I) are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall. For this reason, the role of octreotide in the treatment of these neoplastic lesions is controversial. Nine patients with more than five type I gastric endocrine tumors each!1cmin size, without invasion of the muscularis propria and with Ki-67 index lower than 3%, were treated with long-acting somatostatin analogs for 12 months. After 6 months and again after 12 months, all the patients underwent upper gastrointestinal (GI) endoscopy with multiple biopsies. The plasma chromogranin A (CgA) levels and the gastrin levels in the serum were also determined. In all patients, the gastric neoplastic lesions disappeared after 12 months of somatostatin analog therapy. We also observed a significant reduction of CgA and gastrin levels at 6 and at 12 months of therapy as compared with the baseline values. We demonstrate that somatostatin analog treatment provokes the pathological regression of type I gastric carcinoids. This therapeutic approach should be considered as a valid option in selected patients with multiple type I gastric endocrine tumors. Endocrine-Related Cancer (2008) Introduction Three subtypes of enterochromaffin-like cell (ECL-cell) tumors (carcinoids) have been recognized (Rindi et al. 1993): type I lesions (70 80% of the total) are associated with autoimmune chronic atrophic gastritis (CAG); type II lesions (5 8%) are associated with gastrinomas and they result in Zollinger Ellison syndrome (ZES), most frequently where ZES is associated with multiple endocrine neoplasia type I; type III (15 20%) are sporadic lesions arising in otherwise normal gastric mucosa and there is no evidence of associated hypergastrinemia (Rindi et al. 1993). Neoplastic changes in ECL-cells (types I and II) are often associated with an elevated concentration of gastrin in the serum (Rindi et al. 1993). In fact, gastrin exerts a trophic effect on ECL-cells, which leads to hyperplasia and, in some cases, to gastric endocrine tumors (Waldum et al. 1998, Lehy et al. 2000). In particular, type I tumors occur mostly in women and are rarely symptomatic (Borch et al. 2005). They are non-functioning tumors, typically found during upper GI endoscopy for dyspepsia or for anemia (Borch et al. 1985). Type I tumors frequently present themselves as multiple polyps, usually!1 cm in diameter, localized in the gastric fundus. They are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall (Rindi et al. 1999). These tumors have a good prognosis, with a 5-year survival rate quoted at 96%, which does not differ from an age-matched normal population (Borch et al. 2005, Hosokawa et al. 2005). The European Neuroendocrine Tumor Society (ENETS) Consensus Guidelines (Ruszniewski et al. 2006) have suggested that, in patients with type I ECLomas, annual surveillance is sufficient for patients with tumors!10 mm in diameter. Otherwise, when the tumors are larger, endoscopic resection is Endocrine-Related Cancer (2008) /08/ q 2008 Society for Endocrinology Printed in Great Britain Downloaded from Bioscientifica.com DOI: /ERC at 01/07/ :37:50PM Online version via
2 D Campana et al.: Octreotide-LAR in gastric carcinoids type I recommended for up to six polyps not involving the muscularis propria. In the remaining patients, local surgical tumor resection should be performed. Antral resection to avoid repeated and chronic gastrin stimulation of ECL cells is effective in 80% of type I tumors (Ruszniewski et al. 2006). Although type I gastric endocrine tumors are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall (Rindi et al. 1999), the role of octreotide in the treatment of these neoplastic lesions is controversial (Burkitt & Pritchard 2006, Ruszniewski et al. 2006). For this reason, we evaluated the role of somatostatin analog treatment in type I gastric endocrine tumors. Patients and methods From January 2000 to December 2006, all patients admitted to our unit with gastric endocrine tumors underwent the following study protocol. A baseline visit was made in which personal data, past medical history, and symptoms were collected; blood fasting samples were taken to assess thyroid function, antithyroglobulin, anti-thyroperoxidase and anti-gastric parietal cell antibodies (APCA), the serum gastrin levels, and the plasma levels of chromogranin A (CgA); upper GI endoscopy with multiple biopsies in the antrum, body, fundus, and visible lesions were performed. Pathological analysis were carried out in all the samples in order to classify the type of CAG and the degree of atrophy of the gastric mucosa according to the updated Sydney system classification (Dixon et al. 1996). Furthermore, we evaluated the degree of endocrine cells proliferation (linear, micronodular and adenomatoid hyperplasia, dysplasia) and the presence of endocrine tumors at immunohistochemistry through the evaluation of CgA positive cells (Solcia et al. 1988,1995). Whenever possible, the Ki67 level was measured and histological detection (Giemsa modified stain) of Helicobacter pylori (HP) infection was assessed. All patients underwent endoscopic ultrasonography (US) and abdominal US to rule out the presence of infiltration of the muscular wall, local lymph node involvement, and distant metastases. All patients who had an endocrine tumor of the stomach associated with CAG, more than five neoplastic lesions!1 cm in size localized in the gastric mucosa, absence of invasion of the muscularis propria and a Ki-67 index lower than 3% were included in the study. The therapy protocol was based on the administration of long-acting somatostatin analogs (octreotide-lar, 338 Novartis, Basel, Switzerland) at a dose of 30 mg i.m. every 28 days for 12 months. After 6 months and again after 12 months, all the patients underwent upper GI endoscopy with multiple biopsies in the antrum, body, fundus, and the lesions. We also determined plasma CgA levels (reference value!17 U/l with DAKO CgA ELISA kit, Dako A/S, Copenhagen, Denmark) and gastrin levels in the serum (reference value pg/ml with Immulite-2000 Gastrin assay from Diagnostic Products Corporation, Los Angeles, CA, USA). Ethics The study protocol was approved by the Senior Ethical Committee of the Department of Internal Medicine and Gastroenterology of the University of Bologna and was carried out according to the Helsinki Declaration of human studies. All patients had given their written informed consent to participate in the study. Statistical analysis The descriptive statistics used were mean, S.D., and frequencies. The data of CgA and gastrin were analyzed by the Wilcoxon test. P values of!0.05 were considered statistically significant. The analyses were carried out using the SPSS version 15.0 for Windows XP. Results Forty-six patients were evaluated and nine of them met the inclusion criteria. The epidemiological, endoscopic, and pathological features of these nine patients are shown in Table 1. Five patients (55.6%) were male and four (44.4%) were female; the mean age at the time of diagnosis was 64.4 years (range 38 85). Four patients (44.4%) had autoimmune CAG (atrophy of body and fundus with positive APCA), while the remaining five (55.6%) had a multifocal CAG (diffuse gastric atrophy with negative APCA). At upper GI endoscopy, we found that all the patients had more than 10 lesions in four (44.4%) the lesions were in the gastric fundus, in one in the body, and in four (44.4%) both in the body and fundus (Fig. 1a). The atrophy of the gastric mucosa was mild in three patients (33.3%), moderate in five (55.5%), and severe in one. In eight patients, HP infection was absent. The pathological and immunohistochemical evaluations demonstrated that, in all patients, there was a welldifferentiated gastric endocrine tumor associated with CAG. The mean Ki67 index available in all the patients was 1.3% (range %). Table 2 shows the different macroscopic features (presence and
3 Endocrine-Related Cancer (2008) Table 1 Epidemiological, endoscopic, and pathological features of the nine patients enrolled No. Sex Age (years) Type of gastritis APCA Site of gastric lesions Grade of atrophy HP 1 M 73 AB Neg Fundus Mild Neg 2 M 80 A Pos Fundus Moderate Neg 3 M 44 AB Neg Fundus Moderate Neg 4 F 73 AB Neg Body and fundus Moderate Pos 5 F 53 A Pos Body and fundus Severe Neg 6 M 72 AB Neg Body Moderate Neg 7 M 86 AB Neg Body and fundus Moderate Neg 8 F 46 A Pos Fundus Mild Neg 9 F 53 A Pos Body and fundus Mild Neg A, autoimmune chronic atrophic gastritis; AB, multifocal chronic atrophic gastritis; APCA, anti-gastric parietal cell antibody; HP, Helicobacter pylori. localization of the lesions) and pathological patterns (neoplasia, hyperplasia, or absence of lesions) seen at endoscopy during follow-up. In four out of nine patients (44.4%), regression of all gastric lesions after 6 months of somatostatin analog treatment was found. In the remaining five, a reduction of the number of the lesions was found (Fig. 1b). In all patients, the lesions disappeared after 12 months of somatostatin analog therapy (Fig. 1c). At pathological evaluation, in eight out of the nine patients (88.9%), we observed a regression from well-differentiated endocrine tumor to micronodular hyperplasia after 6 months of treatment. After 12 months, the endocrine cells were normal in four patients (44.4%), while a micronodular hyperplasia was found in four (44.4%) and a linear hyperplasia was found in one (11.1%). The plasma CgA and serum gastrin levels before starting treatment (baseline), after 6 months, and again after 12 months are shown in Fig. 2. We observed a significant reduction of CgA and gastrin levels between baseline values (CgA: 65.2G75.0 U/l; gastrin: G566.4 ng/ml) and after 6 months of therapy (CgA: 33.2G44.2 U/l, PZ0.017; gastrin: 688.4G416.2 ng/ml, PZ0.038), and between baseline values and after 12 months of therapy (CgA: 29.3G 24.5 U/l, PZ0.028; gastrin: 358.1G272.3 ng/ml, PZ0.008). None of the nine patients reported gallbladder stones or sludge after 6 and 12 months of somatostatin analog treatment. Otherwise, eight out of the nine patients reported meteorism for 2 3 days after the first injection of somatostatin analogs. Discussion The management of gastric endocrine tumors is largely dependent upon the subtype and size of the lesion. Type I gastric endocrine tumors, which are associated with CAG and hypergastrinemia, can be treated with various approaches. Hirschowitz et al. (1992) claimed that an antrectomy rather than a total gastrectomy may be the most appropriate treatment for gastric endocrine tumors associated with CAG. Antrectomy in three patients resulted in normalization of the serum gastrin Figure 1 Time course of the endoscopic appearance of gastric endocrine tumors before and after treatment with somatostatin analogs in a 53-year-old female. (a) Multiple gastric endocrine tumors in body and fundus at baseline study, (b) reduction in the number and size of the endocrine tumors in body and fundus at 6 months, and (c) no evidence of macroscopic lesions at 12 months
4 D Campana et al.: Octreotide-LAR in gastric carcinoids type I Table 2 Time course of the macroscopic features and pathological patterns seen at upper GI endoscopy Patient No. Baseline 6 months 12 months Site of lesion at upper endoscopy 1 Fundus Fundus Absent 2 Fundus Fundus Absent 3 Fundus Fundus Absent 4 Body and fundus Body and fundus Absent 5 Body and fundus Body and fundus Absent 6 Body Absent Absent 7 Body and fundus Absent Absent 8 Fundus Absent Absent 9 Body and fundus Absent Absent Pathological pattern a 1 Endocrine tumors Micronodular hyperplasia Normal mucosa 2 Endocrine tumors Micronodular hyperplasia Linear hyperplasia 3 Endocrine tumors Micronodular hyperplasia Normal mucosa 4 Endocrine tumors Micronodular hyperplasia Micronodular hyperplasia 5 Endocrine tumors Endocrine tumors Micronodular hyperplasia 6 Endocrine tumors Adenomatoid hyperplasia Normal mucosa 7 Endocrine tumors Micronodular hyperplasia Micronodular hyperplasia 8 Endocrine tumors Micronodular hyperplasia Normal mucosa 9 Endocrine tumors Micronodular hyperplasia Micronodular hyperplasia a Solcia et al. (1988). levels and in the disappearance of carcinoids in 6 16 weeks, and a follow-up months after antrectomy showed no carcinoids or ECL-cell hyperplasia. Thus, the authors concluded that multicentric ECLomas in patients with pernicious anemia and achlorhydria appeared to be gastrin-dependent and disappeared after the normalization of serum gastrin by an antrectomy. On the contrary, Ahlman et al. have suggested that a prospective treatment protocol for multiple gastric carcinoids with type A gastritis should be the endoscopic removal of less numerous, small lesions as a first-step therapy, followed by an antrectomy at recurrence, while larger lesions should be excised in combination with an antrectomy. Total gastrectomy should be reserved for rare cases of invasive tumors with lymph node metastases (Ahlman et al. 1994). More recently, some reports have suggested that a careful endoscopic follow-up without any treatment might represent a reasonable and safe option in selected patients (Rappel et al. 1995, Hori et al. 2000, Ruszniewski et al. 2006, Ravizza et al. 2007). In a recent study, Hosokawa et al. (2005) enrolled eight patients with multiple gastric endocrine tumors associated with type A gastritis in a follow-up program without surgical resection. These patients were free from the development or metastasis of carcinoids after a mean follow-up of 5.8 years in spite of their continuous hypergastrinemia, and the authors concluded that patients with multiple type I gastric 340 endocrine tumors should not undergo surgical resection, but should instead be followed-up endoscopically. Finally, we found that gastric endocrine tumor regressed in three patients who had ZES and a family history of multiple type I endocrine neoplasia after long-term treatment with somatostatin analogs (Tomassetti et al. 2000). The regression of the tumors was related to the decrease in serum gastrin levels and the hypothetic antiproliferative effect of somatostatin analogs on ECL-cells in both animals and humans (D Adda et al. 1996, Bakke et al. 2000, Tomassetti et al. 2000, Erlandsen et al. 2007). In the present study, we evaluated the effect of this therapy on a selected group of patients aiming to better investigate the putative role of octreotide in type I gastric endocrine tumors. In particular, we chose patients with more than five lesions localized in the body and the fundus having a diameter!1 cm with pathological confirmation of well-differentiated endocrine tumor according to the WHO classification. After 12 months of treatment with long-acting somatostatin analogs, complete regression of the neoplastic lesions in all patients was observed. The pathological examinations showed that, after 6 months, there was a regression from endocrine tumor to micronodular hyperplasia in eight patients (88.9%), while, after 12 months, the neoplasia disappeared in all the patients examined. These data are similar to those previously found by Fykse et al. (2004, 2005) in which
5 Endocrine-Related Cancer (2008) Figure 2 Time course of plasma chromogranin A and serum gastrin values before and after treatment with somatostatin analogs in the nine patients enrolled in the study. the author had treated five patients with one to five gastric endocrine tumors in CAG with octreotide-lar 20 mg for 12 months. Moreover, we obtained the complete regression of endocrine tumors to simple hyperplasia in patients with higher number of lesions using octreotide-lar 30 mg. Furthermore, there are some additional reports of the use of short-term octreotide therapy in patients with type I gastric endocrine tumors in which a reduction of endocrine cells in gastric mucosa after 3 months of treatment was described (Bordi et al. 1993, D Adda et al. 1996). We also found significantly lower CgA levels after 6 months and again after 12 months versus baseline plasma concentrations. This decrease could be due to both an inhibitory effect produced by somatostatin analog treatment on CgA secretion, and pathological changes from neoplasia to hyperplasia, as has already been reported by Peracchi et al. (2005). Finally, a statistically significant reduction in serum gastrin levels during SST analog treatment was also found. Other investigators have reported a similar decrease in serum gastrin levels after long-term treatment with octreotide in patients with ZES (Ruszniewski et al. 1988, Tomassetti et al. 2000) and in those with hypergastrinemic atrophic gastritis (Ferraro et al. 1996). Since hypergastrinemia plays an important role in the pathogenesis of gastric carcinoid tumors in patients with CAG, it is probable that the decrease in serum gastrin levels might have influenced the disappearance of the tumors. In conclusion, we demonstrated that somatostatin analog treatment provokes the pathological regression of type I gastric endocrine tumors. This therapeutic approach should be considered as a valid option in patients with multiple type I gastric endocrine tumors!10 mm of diameter, without muscularis propria invasion or a high proliferation index. In our experience, medical treatment with long-acting somatostatin analogs can be used as a first line therapy and an alternative to follow-up (Ruszniewski et al. 2006, Ravizza et al. 2007). Further studies on a more consistent number of patients are necessary to confirm this initial observation and, most of all, to describe what happens in the long term after the end of treatment. In fact some authors reported a rebound of gastric endocrine cell after drug withdrawal without recurrence of gastric endocrine tumors (Bordi et al. 1993, Fykse et al. 2005). In our experience, according to the ENETS guidelines, antrectomy still remains the treatment of choice in case of malignant development (deep invasion of the gastric wall) or recurrence despite local surgical resection or medical therapy (Ruszniewski et al. 2006). Acknowledgements The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work. References Ahlman H, Kolby L, Lundell L, Olbe L, Wangberg B, Granerus G, Grimelius L & Nilsson O 1994 Clinical management of gastric carcinoid tumors. Digestion 55 (Supplement 3) Bakke I, Sandvik AK & Waldum HL 2000 Octreotide inhibits the enterochromaffin-like cell but not peroxisome proliferator-induced hypergastrinemia. Journal of Molecular Endocrinology Borch K, Renvall H & Liedberg G 1985 Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G & Grimelius L 2005 Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Annals of Surgery
6 D Campana et al.: Octreotide-LAR in gastric carcinoids type I Bordi C, Azzoni C, Pilato FP, Robutti F, D Ambra G, Caruana P, Rindi G, Corleto VD, Annibale B & Delle Fave G 1993 Morphometry of gastric endocrine cells in hypergastrinemic patients treated with the somatostatin analogue octreotide. Regulatory Peptides Burkitt MD & Pritchard DM 2006 Review article: pathogenesis and management of gastric carcinoid tumours. Alimentary Pharmacology and Therapeutics D Adda T, Annibale B, Delle Fave G & Bordi C 1996 Oxyntic endocrine cells of hypergastrinaemic patients. Differential response to antrectomy or octreotide. Gut Dixon MF, Genta RM, Yardley JH & Correa P 1996 Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston American Journal of Pathology Erlandsen SE, Fykse V, Waldum HL & Sandvik AK 2007 Octreotide induces apoptosis in the oxyntic mucosa. Molecular and Cellular Endocrinology Ferraro G, Annibale B, Marignani M, Azzoni C, D Adda T, D Ambra G, Bordi C & Delle Fave G 1996 Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth. Journal of Clinical Endocrinology and Metabolism Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U & Waldum HL 2004 Treatment of ECL cell carcinoids with octreotide LAR. Scandinavian Journal of Gastroenterology Fykse V, Sandvik AK & Waldum HL 2005 One-year followup study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release. Scandinavian Journal of Gastroenterology Hirschowitz BI, Griffith J, Pellegrin D & Cummings OW 1992 Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology Hori K, Fukui H, Imura J, Kojima T, Fujita M, Kawamata H, Chiba T & Fujimori T 2000 Benign gastric carcinoid tumor with hypergastrinemia followed up for 12 years. Gastric Cancer Hosokawa O, Kaizaki Y, Hattori M, Douden K, Hayashi H, Morishita M & Ohta K 2005 Long-term follow up of patients with multiple gastric carcinoids associated with type A gastritis. Gastric Cancer Lehy T, Roucayrol AM & Mignon M 2000 Histomorphological characteristics of gastric mucosa in patients with Zollinger Ellison syndrome or autoimmune gastric atrophy: role of gastrin and atrophying gastritis. Microscopy Research and Technique Peracchi M, Gebbia C, Basilisco G, Quatrini M, Tarantino C, Vescarelli C, Massironi S & Conte D 2005 Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. European Journal of Endocrinology Rappel S, Tendorf-Hofmann A & Stolte M 1995 Prognosis of gastric carcinoid tumours. Digestion Ravizza D, Fiori G, Trovato C, Fazio N, Bonomo G, Luca F, Bodei L, Pelosi G, Tamayo D & Crosta C 2007 Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours. Digestive and Liver Disease Rindi G, Luinetti O, Cornaggia M, Capella C & Solcia E 1993 Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology Rindi G, Azzoni C, La RS, Klersy C, Paolotti D, Rappel S, Stolte M, Capella C, Bordi C & Solcia E 1999 ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology Ruszniewski P, Laucournet H, Elouaer-Blanc L, Mignon M & Bonfils S 1988 Long-acting somatostatin (SMS ) in the management of Zollinger Ellison syndrome: evidence for sustained efficacy. Pancreas Ruszniewski P, Delle Fave G, Cadiot G, Komminoth P, Chung D, Kos-Kudla B, Kianmanesh R, Hochhauser D, Arnold R, Ahlman H et al Well-differentiated gastric tumors/carcinomas. Neuroendocrinology Solcia E, Bordi C, Creutzfeldt W, Dayan Y, Falkmer S, Grimelius L & Havu N 1988 Histopathological classification of nonantral gastric endocrine growths in man. Digestion Solcia E, Fiocca R, Villani L, Luinetti O & Capella C 1995 Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa. Classification and histogenesis. American Journal of Pathology 19 (Suppl 1) S1 S7. Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R & Gullo L 2000 Treatment of type II gastric carcinoid tumors with somatostatin analogues. New England Journal of Medicine Waldum HL, Sandvik AK & Idle JR 1998 Gastrin is the most important factor in ECL tumorigenesis. Gastroenterology
Original Report. Carcinoid Tumors of the Stomach: A Clinical and Radiographic Study
Aaron J. Binstock 1 C. Daniel Johnson 1 David H. Stephens 1 Ricardo V. Lloyd 2 Joel G. Fletcher 1 Received July 25, 2000; accepted after revision September 29, 2000. 1 Department of Radiology, Mayo Clinic,
More informationNeuroendocrine neoplasms of the stomach
Neuroendocrine neoplasms of the stomach Oldrich Louthan Background. Gastric neuroendocrine neoplasms of type 1 and type 3 are different entities and as such require different therapeutical strategies.
More informationEndoscopic argon plasma therapy for neuroendocrine type I gastric tumors
Original articles Endoscopic argon plasma therapy for neuroendocrine type I gastric tumors Rodrigo Castaño, MD, Claudia Vargas, MD, Juan Camilo Pérez Cadavid, MD, Juan Pablo Dueñas, MD, Mario Hernán Ruiz,
More informationRecent Studies on Digestive. System Anatomy
Chapter 1 Recent Studies on Digestive Study on Morphology and Pathogenesis of Type 1 ECL- Cell Gastric Carcinoids Vuka Katic Department in Policlinic Human, University of Niš, Serbia. Email : vuka.katic@gmail.com
More informationIs Endoscopic Resection for Type 1 Gastric Neuroendocrine Tumors Essential for Treatment?: Multicenter, Retrospective Long-term Follow-up Results
ORIGINAL ARTICLE ISSN 1738-3331, http://dx.doi.org/10.7704/kjhugr.2016.16.1.13 The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2016;16(1):13-18 Is Endoscopic Resection for Type
More informationPathogenesis of ECL Cell Tumors in Humans
YALE JOURNAL OF BIOLOGY AND MEDICINE 71 (1998), pp. 273-284. Copyright C) 1999. All rights reserved. Pathogenesis of ECL Cell Tumors in Humans Cesare Bordia, Tiziana D'Adda, Cinzia Azzoni and Gabriella
More informationPrinciples of diagnosis, work-up and therapy The Gastroenterologist s role
Principles of diagnosis, work-up and therapy The Gastroenterologist s role Dr. Christos G. Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University
More informationEndocrine pancreatic tumors: factors correlated with survival
Original article Annals of Oncology 6: 86 8, 25 doi:.93/annonc/mdi358 Published online 5 August 25 Endocrine pancreatic tumors: factors correlated with survival P. Tomassetti *, D. Campana, L. Piscitelli,
More informationCarcinoid Tumors: The Beginning and End. Surgical Oncology Update 2011 Chris Baliski MD, FRCS BC Cancer Agency, CSI October 21, 2011
Carcinoid Tumors: The Beginning and End Surgical Oncology Update 2011 Chris Baliski MD, FRCS BC Cancer Agency, CSI October 21, 2011 1 st described by Oberndofer(1907) Karzinoide = cancer like Arise from
More informationCASE REPORT. Introduction. Case Report. Kimitoshi Kubo 1, Noriko Kimura 2, Katsuhiro Mabe 1, Yusuke Nishimura 1 and Mototsugu Kato 1
doi: 10.2169/internalmedicine.0842-18 Intern Med 57: 2951-2955, 2018 http://internmed.jp CASE REPORT Synchronous Triple Gastric Cancer Incorporating Mixed Adenocarcinoma and Neuroendocrine Tumor Completely
More informationENDOLUMINAL APPROACH FOR THE MANAGEMENT OF GASTROINTESTINAL CARCINOID
ENDOLUMINAL APPROACH FOR THE MANAGEMENT OF GASTROINTESTINAL CARCINOID Manoop S. Bhutani, MD, FASGE, FACG, FACP, AGAF, Doctor Honoris Causa Professor of Medicine Eminent Scientist of the Year 2008, World
More informationUpper gastrointestinal carcinoid tumors incidentally found by endoscopic examinations
PO Box 2345, Beijing 100023, China World J Gastroenterol 2005;11(44):7028-7032 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com ELSEVIER 2005 The WJG Press and Elsevier Inc.
More informationClinical features and management of type I gastric carcinoids
Clin J Gastroenterol (2014) 7:381 386 DOI 10.1007/s28-014-0528-9 CLINICAL REVIEW Clinical features and management of type I gastric carcinoids Yuichi Sato Received: 20 August 2014 / Accepted: 2 September
More informationType 2 gastric neuroendocrine tumor: report of one case
Case Report Type 2 gastric neuroendocrine tumor: report of one case Yuanliang Li, Xin Su, Huangying Tan Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing 100029, China Correspondence
More informationSomatostatin analogs for gastric carcinoids: for many, but not all
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v21.i22.6785 World J Gastroenterol 2015 June 14; 21(22): 6785-6793 ISSN 1007-9327 (print)
More informationECL Cell Tumor and Poorly Differentiated Endocrine Carcinoma of the Stomach: Prognostic Evaluation by Pathological Analysis
GASTROENTEROLOGY 1999;116:532 542 ECL Cell Tumor and Poorly Differentiated Endocrine Carcinoma of the Stomach: Prognostic Evaluation by Pathological Analysis GUIDO RINDI,* CINZIA AZZONI, STEFANO LA ROSA,
More informationJeffrey L. Winslow, MD, 1 Thomas D. Trainer, MD, 1 and Richard B. Colletti, MD 2. Abstract
Anatomic Pathology / COLLAGENOUS GASTRITIS Collagenous Gastritis A Long-Term Follow-up With the Development of Endocrine Cell Hyperplasia, Intestinal Metaplasia, and Epithelial Changes Indeterminate for
More informationSpontaneous enterochromaffin-like cell carcinomas in cotton rats (Sigmodon hispidus) are prevented by a somatostatin analogue
Endocrine-Related Cancer (2004) 11 149 160 Spontaneous enterochromaffin-like cell carcinomas in cotton rats (Sigmodon hispidus) are prevented by a somatostatin analogue R Fossmark, T C Martinsen, S H Torp
More informationGastrinoma: Medical Management. Haley Gallup
Gastrinoma: Medical Management Haley Gallup Also known as When to put your knife down Gastrinoma Definition and History Diagnosis Historic Management Sporadic vs MEN-1 Defining surgical candidates Nonsurgical
More informationCase Report Features of the Atrophic Corpus Mucosa in Three Cases of Autoimmune Gastritis Revealed by Magnifying Endoscopy
Volume 2012, Article ID 368160, 4 pages doi:10.1155/2012/368160 Case Report Features of the Atrophic Corpus Mucosa in Three Cases of Autoimmune Gastritis Revealed by Magnifying Endoscopy Kazuyoshi Yagi,
More informationGastrointestinal pathology 2018 lecture 4. Dr Heyam Awad FRCPath
Gastrointestinal pathology 2018 lecture 4 Dr Heyam Awad FRCPath Topics to be covered Peptic ulcer disease Hiatal hernia Gastric neoplasms Peptic ulcer disease (PUD)= chronic gastric ulcer Causes H pylori
More informationMultifocal Gastric Carcinoid Tumor in a Patient with Pernicious Anemia Receiving Lansoprazole
Digestive Diseases and Sciences, Vol. 50, No. 3 (March 2005), pp. 509 513 ( C 2005) DOI: 10.1007/s10620-005-2466-3 CASE REPORT Multifocal Gastric Carcinoid Tumor in a Patient with Pernicious Anemia Receiving
More informationThe pathology of neuroendocrine tumours of the gut
The pathology of neuroendocrine tumours of the gut Professor Neil A Shepherd Gloucester & Cheltenham, UK Histopathology Regional Teaching Bristol May 11 2016 The pathology of neuroendocrine tumours (NETs)
More informationAssociation of Helicobacter pylori infection with Atrophic gastritis in patients with Dyspepsia
ADVANCES IN BIORESEARCH Adv. Biores., Vol 8 [3] May 2017: 137-141 2017 Society of Education, India Print ISSN 0976-4585; Online ISSN 2277-1573 Journal s URL:http://www.soeagra.com/abr.html CODEN: ABRDC3
More informationColor Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging
Saturday, November 5, 2005 8:30-10:30 a. m. Poorly Differentiated Endocrine Carcinomas Chairman: E. Van Cutsem, Leuven, Belgium 9:00-9:30 a. m. Working Group Sessions Pathology and Genetics Group leaders:
More informationUnexpected Findings at Endoscopy
The Endoscopic Incidentaloma: What to Tell Your Patient t with Unexpected Endoscopic Findings: Gastric Intestinal Metaplasia, Silent Ileitis, Carcinoid David Greenwald, MD Montefiore Medical Center Albert
More informationDisclosure of Relevant Financial Relationships
Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS
More informationGastric and Oesophageal Neuroendocrine tumours. Dr Tim Bracey, Consultant Pathologist MBChB PhD MRCS FRCPath
Gastric and Oesophageal Neuroendocrine tumours Dr Tim Bracey, Consultant Pathologist MBChB PhD MRCS FRCPath Intestinal (and BO) endocrine cells in crypt bases NE cell (granules towards vessels) Paneth
More informationNET und NEC. Endoscopic and oncologic therapy
NET und NEC Endoscopic and oncologic therapy Classification well-differentiated NET - G1 and G2 - carcinoid poorly-differentiated NEC - G3 - like SCLC well differentiated NET G3 -> elevated proliferation
More informationGastric Polyps. Bible class
Gastric Polyps Bible class 29.08.2018 Starting my training in gastroenterology, some decades ago, my first chief always told me that colonoscopy may seem technically more challenging but gastroscopy has
More informationCommonly Encountered Neuro-Endocrine Tumors of the Gut
Commonly Encountered Neuro-Endocrine Tumors of the Gut Moderators: Giuseppe Aliperti, MD Steven Edmundowicz, MD Panelists Douglas O. Faigel, MD Professor of Medicine Department of Gastroenterology Oregon
More informationSurgical Management of Neuroendocrine Tumors of the Gut. Richard Hodin MD Professor of Surgery Massachusetts General Hospital Harvard Medical School
Surgical Management of Neuroendocrine Tumors of the Gut Richard Hodin MD Professor of Surgery Massachusetts General Hospital Harvard Medical School Sites of GI Carcinoid Tumors Small intestine 44% Rectum
More informationProtocol for the Examination of Specimens From Patients With Neuroendocrine Tumors (Carcinoid Tumors) of the Stomach
Protocol for the Examination of Specimens From Patients With Neuroendocrine Tumors (Carcinoid Tumors) of the Stomach Protocol applies to well-differentiated neuroendocrine tumors of the stomach. Carcinomas
More informationSUMMARY INTRODUCTION. Aliment Pharmacol Ther 2000; 14: 625±634. Accepted for publication 20 January 2000
Aliment Pharmacol Ther 2000; 14: 625±634. Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects
More informationAltered Distribution of Metaplastic Paneth, Gastrin and Pancreatic Acinar Cells in Atrophic Gastritic Mucosa with Endocrine Cell Lesions
Tohoku J. Exp. Med., Paneth, 2004, Acinar 202, and 13-22 G-Cells in Gastric Endocrine Cell Lesions 13 Altered Distribution of Metaplastic Paneth, Gastrin and Pancreatic Acinar Cells in Atrophic Gastritic
More informationRESEARCH COMMUNICATION
PPI in Helicobacter pylori-infected Mongolian gerbils Enhances Neuroendocrine Tumor Development RESEARCH COMMUNICATION Long-term High-dose Proton Pump Inhibitor Administration to Helicobacter pylori-infected
More informationGastric atrophy: use of OLGA staging system in practice
Gastroenterology and Hepatology From Bed to Bench. 2016 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE Gastric atrophy: use of OLGA staging system in practice Mahsa
More informationUpdate on the pathological classification of gastritis. Hala El-Zimaity, M.D. M.S. Epidemiology McMaster University Hamilton, Ontario Canada
Update on the pathological classification of gastritis Hala El-Zimaity, M.D. M.S. Epidemiology McMaster University Hamilton, Ontario Canada CLASSIFICATION GASTRITIS GASTROPATHY 1. Acute 2. Chronic 3. Uncommon
More informationThe surface mucous cells and the cardiac and pyloric glands secrete mucus which protects the stomach from self-digestion.
PATHOLOGY OF THE STOMACH Stomach mucosa Gastric mucosa is covered by a layer of mucus. The mucosal glands comprise the cardiac glands, the fundic glands in the fundus and body of the stomach, and the pyloric
More informationSporadic versus hereditary gastrinomas of the duodenum and pancreas: Distinct clinico-pathological and epidemiological features
PO Box 2345, Beijing 100023, China World J Gastroenterol 2006 September 14; 12(34): 5440-5446 World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com 2006 The WJG Press. All rights reserved. EDITORIAL
More informationEndoscopic Corner CASE 1. Sirimontaporn N Klaikaew N Imraporn B Rerknimitr R
Endoscopic Corner Sirimontaporn N, et al. THAI J GASTROENTEROL 2010 Vol. 11 No. 3 Sept. - Dec. 2010 171 Sirimontaporn N Klaikaew N Imraporn B Rerknimitr R CASE 1 A 47- year-old female presented to the
More informationDefinition gastritis
Gastritis Definition The term gastritis is used to denote inflammation associated with mucosal injury Gastritis is mostly a histological term that needs biopsy to be confirmed Gastritis is usually due
More informationEthnic Distribution of Atrophic Autoimmune Gastritis in the United States
Ethnic Distribution of Atrophic Autoimmune Gastritis in the United States Robert M. Genta, Regan Allen, Massimo Rugge Miraca Life Sciences Research Institute, Miraca Life Sciences, Irving, Texas UTSW University
More informationIntroduction. Original articles. Nicolás Rocha, 1 Sandra Huertas, 2 Rosario Albis, 3 Diego Aponte, 4 Luis Carlos Sabbagh. 5
Original articles Correlation of endoscopic and histological findings in diagnosis of gastrointestinal metaplasia in patients referred to the Clinica Colombia for upper endoscopies Nicolás Rocha, 1 Sandra
More informationDOCTORAL THESIS SUMMARY
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL THESIS HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY OF GASTRIC CARCINOMAS SUMMARY Scientific Coordinator: Univ. Prof. Dr. SIMIONESCU CRISTIANA EUGENIA
More informationImmunohistochemical consistency between primary tumors and lymph node metastases of gastric neuroendocrine carcinoma
Uchiyama et al. World Journal of Surgical Oncology 2012, 10:115 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Immunohistochemical consistency between primary tumors and lymph node metastases
More informationProtocol for the Examination of Specimens From Patients With Neuroendocrine Tumors (Carcinoid Tumors) of the Stomach
Protocol for the Examination of Specimens From Patients With Neuroendocrine Tumors (Carcinoid Tumors) of the Stomach Version: Protocol Posting Date: June 2017 Includes ptnm requirements from the 8 th Edition,
More informationPrognostic analysis of gastric mucosal dysplasia after endoscopic resection: A single-center retrospective study
JBUON 2019; 24(2): 679-685 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Prognostic analysis of gastric mucosal dysplasia after endoscopic resection:
More informationBritish Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology Br J Clin Pharmacol (2016) 1 CLINICAL TRIALS Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients
More informationOriginal Article Increased lysozyme expression in gastric biopsies with intestinal metaplasia and pseudopyloric metaplasia
www.ijcem.com/ijcem908003 Original Article Increased lysozyme in gastric biopsies with intestinal metaplasia and pseudopyloric metaplasia Carlos A Rubio, Ragnar Befrits Gastrointestinal and Liver Pathology
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationSession 5: Morphology and Pathogenesis of Endocrine Hyperplasias, Precarcinoid Lesions, and Carcinoids Arising in Chronic Atrophic Gastritis
Scandinavian Journal of Gastroenterology ISSN: 0036-5521 (Print) 1502-7708 (Online) Journal homepage: http://www.tandfonline.com/loi/igas20 Session 5: Morphology and Pathogenesis of Endocrine Hyperplasias,
More informationNeuroendocrine Tumors
Neuroendocrine Tumors Neuroendocrine tumors arise from cells that release a hormone in response to a signal from the nervous system. Neuro refers to the nervous system. Endocrine refers to the hormones.
More informationGI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust
GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust Introduction Carcinoid was old term, introduced in 1906 by German pathologist Cancinoma like More recent
More informationAN ARGUMENT FOR SURGERY FOR GASTRINOMA. Lauren Wilson R1 General Surgery
AN ARGUMENT FOR SURGERY FOR GASTRINOMA Lauren Wilson R1 General Surgery WHAT IS A GASTRINOMA? Gastrin secreting cells derived from multipotential stem cells of endodermal origin or enteroendocrine cells
More informationCross-sectional Imaging of Neuroendocrine Tumors of the Gastrointestinal Tract
Cross-sectional Imaging of Neuroendocrine Tumors of the Gastrointestinal Tract Eric J. May 1, Shannon P. Sheedy 1, Joel G. Fletcher 1, Mark J. Truty 2, Thomas C. Smyrk 3, Jeff L. Fidler 1 1. Radiology,
More informationHelicobacter pylori Improved Detection of Helicobacter pylori
DOI:http://dx.doi.org/10.7314/APJCP.2016.17.4.2099 RESEARCH ARTICLE Improved Detection of Helicobacter pylori Infection and Premalignant Gastric Mucosa Using Conventional White Light Source Gastroscopy
More informationNEUROENDOCRINE CARCINOID TUMORS PANCREATIC NEUROENDOCRINE TUMORS
University of Miami Jackson Memorial Hospital Role of the Surgeon in the Approach to Neuroendocrine tumors Dido Franceschi, MD Professor of Surgery University of Miami Karzinoide Siegfried Oberndorfer,
More informationRare GI Malignancies
Rare GI Malignancies Jordan Karlitz, MD Associate Professor of Medicine, Division of Gastroenterology Director, Hereditary GI Cancer and Genetics Program Tulane University School of Medicine Outline Gastrointestinal
More informationEndoscopic Treatment of Duodenal Neuroendocrine Tumors
CASE REPORT Clin Endosc 2013;46:656-661 Print ISSN 2234-2400 / On-line ISSN 2234-2443 http://dx.doi.org/10.5946/ce.2013.46.6.656 Open Access Endoscopic Treatment of Duodenal Neuroendocrine Tumors Sang
More informationÐÑÏÓÊÅÊËÇÌÅÍÅÓ ÎÅÍÏÃËÙÓÓÅÓ ÁÍÁÊÏÉÍÙÓÅÉÓ ÅËËÇÍÙÍ ÅÑÅÕÍÇÔÙÍ
ÐÑÏÓÊÅÊËÇÌÅÍÅÓ ÎÅÍÏÃËÙÓÓÅÓ ÁÍÁÊÏÉÍÙÓÅÉÓ ÅËËÇÍÙÍ ÅÑÅÕÍÇÔÙÍ 205 206 ÐÑÏÓÊÅÊËÇÌÅÍÅÓ ÎÅÍÏÃËÙÓÓÅÓ ÁÍÁÊÏÉÍÙÓÅÉÓ ÅËËÇÍÙÍ ÅÑÅÕÍÇÔÙÍ EPITHELIAL CELL TURNOVER IN NON-DYSPLASTIC GASTRIC MUCOSA ADJACENT TO EARLY AND
More informationPeptic ulcer disease. Nomin-Erdene. D SOM-531
Peptic ulcer disease Nomin-Erdene. D SOM-531 Learning objectives Stomach gross anatomy PUD Epidemiology Pathogenesis Clinical manifestation Diagnosing Treatment Complicated ulcer disease Surgical procedures
More informationHistopathology: gastritis and peptic ulceration
Histopathology: gastritis and peptic ulceration These presentations are to help you identify, and to test yourself on identifying, basic histopathological features. They do not contain the additional factual
More informationEndoscopic treatment of Gastrointestinal Neuroendocrine tumors (GI-NETs)
Endoscopic treatment of Gastrointestinal Neuroendocrine tumors (GI-NETs) Apostolos Tsolakis M.D., Ph.D. apostolos.tsolakis@ki.se or apobtsol@hotmail.com Dept. of Oncology and Pathology, Karolinska Institute,
More informationEDUCATION PRACTICE. Diagnosis of the Zollinger Ellison Syndrome. Clinical Scenario. The Problem. Hypergastrinemia
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:126 130 EDUCATION PRACTICE Diagnosis of the Zollinger Ellison Syndrome DAVID C. METZ Division of Gastroenterology, Hospital of the University of Pennsylvania,
More informationRESEARCH COMMUNICATION
Eradication in Helicobacter pylori Impacts on Carcinoid Tumors in Mongolian Gerbils RESEARCH COMMUNICATION Development of Carcinoid Tumors of the Glandular Stomach and Effects of Eradication in Helicobacter
More informationRelevance of vitamin D deficiency in patients with chronic autoimmune atrophic gastritis: a prospective study
Massironi et al. BMC Gastroenterology (2018) 18:172 https://doi.org/10.1186/s12876-018-0901-0 RESEARCH ARTICLE Relevance of vitamin D deficiency in patients with chronic autoimmune atrophic gastritis:
More informationSurgical Therapy of GEP-NET: An Overview
Surgical Therapy of GEP-NET: An Overview Pierce K.H Chow MBBS, MMed, FRCSE, FAMS, PhD Professor, Duke-NUS Graduate School of Medicine Senior Consultant Surgeon, Singapore General Hospital Visiting Senior
More informationSurgical treatment of neuroendocrine metastases
Best Practice & Research Clinical Gastroenterology Vol. 19, No. 4, pp. 577 583, 2005 doi:10.1016/j.bpg.2005.04.003 available online at http://www.sciencedirect.com 6 Surgical treatment of neuroendocrine
More informationGastrointestinal Tract Cancer
Gastrointestinal Tract Cancer Tumors of the Stomach Gastric adenocarcinoma Incidence and Epidemiology Incidence mortality rates USA High incidence: Japan, China, Chile, Ireland risk lower socioeconomic
More informationGrade 2 Ileum NET with liver and bone metastasis
Grade 2 Ileum NET with liver and bone metastasis BERNARDO MARQUES ENDOCRINOLOGY DEPARTMENT PORTUGUESE INSTITUTE OF ONCOLOGY - COIMBRA April 2018, Lugano, Switzerland JPB, male, 67 years old April 2015
More informationThe incidence of neoplasia in patients with autoimmune metaplastic atrophic gastritis: a renewed call for surveillance
ORIGINAL ARTICLE Annals of Gastroenterology (2019) 32, 1-6 The incidence of neoplasia in patients with autoimmune metaplastic atrophic gastritis: a renewed call for surveillance Nadim Mahmud a, Kristen
More informationPathology of the oesophagus and the stomach. Neil A Shepherd Gloucester, UK. Bristol Pathology 1 st Year Training School, The layers of the GI tract
Pathology of the oesophagus and the stomach Neil A Shepherd Gloucester, UK Bristol Pathology 1 st Year Training School, The layers of the GI tract 1 Some facts about Histopathology and the upper GI tract
More informationOverview of digestion or, gut reactions - to food
1 Key concepts in Digestion. Indigestion module Overview of digestion or, gut reactions to food Prof. Barry Campbell Gastroenterology Cellular & Molecular Physiology email: bjcampbl@liv.ac.uk http://pcwww.liv.ac.uk/~bjcampbl
More informationSurveillance of Small Rectal Carcinoid Tumors in the Absence of Metastatic Disease
Ann Surg Oncol (2012) 19:3486 3490 DOI 10.1245/s10434-012-2442-z ORIGINAL ARTICLE ENDOCRINE TUMORS Surveillance of Small Rectal Carcinoid Tumors in the Absence of Metastatic Disease Sara E. Murray, MD
More informationHELICOBACTER PYLORI causes chronic gastritis
8 THE NEW ENGLAND JOURNAL OF MEDICINE April 8, 6 ATROPHIC GASTRITIS AND HELICOBACTER PYLORI INFECTION IN PATIENTS WITH REFLUX ESOPHAGITIS TREATED WITH OMEPRAZOLE OR FUNDOPLICATION ERNST J. KUIPERS, M.D.,
More informationPATHOLOGY OF NON NEOPLASTIC LESIONS OF THE UPPER GASTROINTESTINAL TRACT.
PATHOLOGY OF NON NEOPLASTIC LESIONS OF THE UPPER GASTROINTESTINAL TRACT. OESOPHAGEAL LESIONS OESOPHAGITIS AND OTHER NON NEOPLASTIC DISORDERS Corrosive Gastroesophageal reflux (GERD), Pills, Acid intake,
More informationGastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
More informationOverview of digestion or, gut reactions - to food
Key concepts in Digestion. Indigestion module Overview of digestion or, gut reactions - to food Prof. Barry Campbell Gastroenterology Cellular & Molecular Physiology e-mail: bjcampbl@liv.ac.uk http://pcwww.liv.ac.uk/~bjcampbl
More informationReview article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors
Aliment Pharmacol Ther 2000; 14: 651±668. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors L. LAINE*, D. AHNEN, C.MCCLAINà, E.SOLCIA &J.H.WALSH±
More informationDiagnosis abnormal morphology and /or abnormal biochemistry
Diagnosis abnormal morphology and /or abnormal biochemistry MEN 1 GEP Tumours Pancreatico-Nodal (-Duodenal) Affects 35-80% of MEN1 patients Functioning or non functioning Hyperplasia microadenoma macrotumours
More informationPathobiology and Management of Hypergastrinemia and the Zollinger-Ellison Syndrome
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 65 (1992), 659-676 Pathobiology and Management of Hypergastrinemia and the Zollinger-Ellison Syndrome BASIL I. HIRSCHOWITZ, M.D. Division of Gastroenterology, University
More informationOberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide)
GEP-NET Adel K. El-Naggar, M.D., Ph.D. The University of Texas MD Anderson Cancer Center, Houston, Texas Oberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide) 1 Histogenesis 16 different
More informationAutoimmune gastritis presenting as iron deficiency anemia in childhood
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v20.i42.15780 World J Gastroenterol 2014 November 14; 20(42): 15780-15786 ISSN 1007-9327
More informationHypochlorhydria and Achlorhydria Are Associated With False-Positive Secretin Stimulation Testing for Zollinger-Ellison Syndrome
ORIGINAL ARTICLE Hypochlorhydria and Achlorhydria Are Associated With False-Positive Secretin Stimulation Testing for Zollinger-Ellison Syndrome Pari Shah, MD, MSCE,* Maneesh H. Singh, MD,Þ Yu-Xiao Yang,
More informationOriginal Article. Abstract
Original Article Association of helicobacter pylori with carcinoma of stomach Muhammad Arif, Serajuddaula Syed Department of Pathology, Sindh Medical College, Karachi Abstract Objective: To note the association
More informationGastric collision between a papillotubular adenocarcinoma and a gastrinoma in a patient with Zollinger-Ellison syndrome
Gastric collision between a papillotubular adenocarcinoma and a gastrinoma in a patient with Zollinger-Ellison syndrome Laurence de Leval a, Noëlle Hardy a, Manuel Deprez a, Jean Delwaide b, Jacques Belaïche
More informationThe Association of CagA + Helicobacter pylori Infection and Gastric Carcinoma
The Association of CagA + Helicobacter pylori Infection and Gastric Carcinoma PRESENTER: Dr. Md. Khalilur Rahman Student of M.D.(Internal Medicine) Sylhet MAG Osmani Medical College Gastric Cancer- ranked
More informationCase Report A Perplexing Case of Abdominal Pain That Led to the Diagnosis of Zollinger-Ellison Syndrome
Hindawi Case Reports in Gastrointestinal Medicine Volume 2017, Article ID 7636952, 4 pages https://doi.org/10.1155/2017/7636952 Case Report A Perplexing Case of Abdominal Pain That Led to the Diagnosis
More informationPrognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours Ulrich-Frank Pape 1 *, Uta Berndt 1 *, Jacqueline Müller-Nordhorn 2, Michael Böhmig 1,4, Stephanie Roll 2, Martin
More informationEndoscopic Resection of Ampullary Neuroendocrine Tumor
CASE REPORT Endoscopic Resection of Ampullary Neuroendocrine Tumor Hiroyuki Fukasawa, Shigetaka Tounou, Masashi Nabetani and Tomoki Michida Abstract We report the case of a 57-year-old man with a 1.0-cm
More informationStomach. R.B. Kolachalam, MD
Stomach R.B. Kolachalam, MD Relevent Anatomy 1.four regions: Cardia, Fundus, Body, and the Pylorus 2. fixed in two locations- at the GEJ and the duodenum Gastric Anatomy body of the stomach: site of mechanical
More informationSandostatin LAR. Sandostatin LAR (octreotide acetate) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.09 Subject: Sandostatin LAR Page: 1 of 5 Last Review Date: March 16, 2018 Sandostatin LAR Description
More informationInhibition of acid and gastric carcinoids
Leading article Gut, 1985, 26, 1279-1283 Inhibition of acid and gastric carcinoids Control of gastric acid secretion has long been one of the principal aims of medical and surgical approach to the management
More informationOriginal article. M. Cimitan 1 *, A. Buonadonna 2, R. Cannizzaro 3, V. Canzonieri 4, E. Borsatti 1, R. Ruffo 1 & L. De Apollonia 5.
Original article Annals of Oncology 14: 1135 1141, 2003 DOI: 10.1093/annonc/mdg279 Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors
More informationhyperplasia of gastric argyrophil cells and multiple gastric carcinoids. We report a patient with long-standing pernicious
Gut, 1981, 22, 237-241 Case report Diffuse enterochromaffin-like (ECL) cell hyperplasia and multiple gastric carcinoids: a complication of pernicious anaemia J R HODGES*, P ISAACSON, AND RALPH WRIGHT From
More informationMarked increase in gastric acid secretory capacity after omeprazole treatment
Gut 1996; 39: 649-653 649 Department of Medicine, University Hospital and Department of Physiology and Biomedical Engineering, Norwegian University of Science and Technology, Trondheim, Norway H J Waldum
More informationColonic Polyp. Najmeh Aletaha. MD
Colonic Polyp Najmeh Aletaha. MD 1 Polyps & classification 2 Colorectal cancer risk factors 3 Pathogenesis 4 Surveillance polyp of the colon refers to a protuberance into the lumen above the surrounding
More informationStomach! First, a few pitfalls. Case Presentations: Gastric Polyps and The Company They Keep - Gastritis
Case Presentations: Gastric Polyps and The Company They Keep - Gastritis Elizabeth Montgomery, MD Department of Pathology Johns Hopkins Hospital Baltimore MD Stomach! We will begin with a whirwind tour
More information